ATAbhishek Tyagi

Abhishek Tyagi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abhishek Tyagi has a total of 174 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    GABA shunt metabolism drives smoking-related peri-neuronal brain metastasis by hijacking synaptic signaling

    by Shih-Ying Wu, Abhishek Tyagi, Eleanor C Smith, Jung‑Shun Lee, Pang‑Shuo Perng, Yu-Min Kuo, Tzu-Feng Wang, Hui-Fang Chen, Ravindra Pramod Deshpande, Jee Won Kim, et al.

    Background: Brain metastases are a major clinical challenge with poor prognosis, particularly in patients with a history of smoking. While neurons are abundant in the brain and capable of synaptic interaction with tumor cells, their role in brain metastasis remains poorly understood. Emerging evidence suggests that neuronal activity may contribute to metastatic progression, yet the mechanisms by which smoking alters the brain microenvironment to promote tumor growth are unclear. Methods: We examined the impact of nicotine exposure on microglia-neuron-tumor interactions in brain metastasis models using in vivo and ex vivo approaches. We analyzed patient-derived brain metastatic tissues, performed molecular and metabolic profiling, and utilized pharmacologic inhibition strategies to dissect the underlying mechanisms of tumor-neuron communication. Results: Our findings reveal a significant association between smoking history and perineural invasion in brain metastases. Nicotine exposure stimulates microglia to release exosomal miR-32-3p, which activates GABAergic neurons and enhances gamma-aminobutyric acid (GABA) release. GABA acts as a metabolic substrate in the tumor microenvironment, fueling tumor growth through the GABA shunt pathway. Pharmacological inhibition of GABA uptake with FDA-approved GABA transporter (GAT) inhibitors Tiagabine and NO-711 significantly suppress brain metastatic progression in vivo. Conclusions: This study identifies a novel GABAergic neuron-microglia-tumor signaling axis by which smoking promotes brain metastasis via GABAergic metabolic reprogramming. Targeting GABA uptake on tumor cells using repurposed anticonvulsant drugs offers a promising therapeutic strategy, particularly for patients with smoking-associated brain metastases.

  • MyD88-mediated chimaeric antigen receptor macrophages suppress brain metastasis using target-specific phagocytosis

    by Shih-Ying Wu, Abhishek Tyagi, Kerui Wu, Eleanor C. Smith, Qianqian Song, Sambad Sharma, Lance D. Miller, Wei Zhang, Bo-Syong Pan, Hui-Kuan Lin, et al.

    Metastatic brain disease occurs in up to 30% of patients with lung, melanoma and breast cancers, and the median survival time remains less than a year. Treating these patients is a challenge because surgical approaches are limited and most chemotherapeutic drugs and immunotherapies are ineffective at crossing the blood–brain barrier (BBB). Given the unique abilities of macrophages to cross the BBB and exert their phagocytic function on tumour cells, we genetically engineer macrophages that express a chimaeric antigen receptor (CAR) targeting mesothelin (MSLN). To specifically target metastatic brain tumours, we fused the cells with the immune signalling molecule MyD88. This chimaeric antigen receptor macrophage (CARMA) penetrates the BBB and decreases brain metastasis growth in a humanized mouse model. MSLN–CARMA shows antigen-specific phagocytosis activity against tumour cells and exhibits a bystander effect by releasing TNF to act on surrounding tumour cells lacking the tumour antigen. These features of CARMA represent advantages over other immune therapies and CARMA may serve as a promising therapeutic tool for the treatment of brain metastasis.


  • Open Access

    Ghrelin-induced neuronal NPY promotes brain metastasis in lung cancer patients with low BMI

    by Abhishek Tyagi, Shih-Ying Wu, Jee-Won Kim, Ravindra Pramod Deshpande, Kerui Wu, Eleanor C. Smith, Giuseppe L. Banna, Kounosuke Watabe

    Obesity is a known risk factor for many cancers, yet recent studies reveal a paradoxical association between low body mass index (BMI) and increased brain metastasis in lung cancer—referred to as the “obesity paradox,” with unclear molecular mechanism(s). Here, we show a significantly higher incidence of brain metastasis in low-BMI lung cancer patients compared to those with high-BMI or other cancer brain metastasis in a pan-analysis of 7628 patients. Mechanistically, low BMI activates ghrelin-GHSR signaling, increasing neuronal neuropeptide Y (NPY) secretion, which promotes tumor metabolic reprogramming via NPY-Y5R, facilitating brain colonization. Elevated plasma ghrelin levels in cancer-free low-BMI subjects suggest its potential as a prognostic biomarker for predicting brain metastasis. Notably, targeting NPY-Y5R or reversing low BMI effectively suppresses brain metastasis, supporting its pro-metastatic role. These findings provide a strong rationale for developing targeted interventions to treat or prevent brain metastasis in lung cancer patients with low BMI.


  • Retraction
    Open Access

    Retraction Note: Nicotine promotes breast cancer metastasis by stimulating N2 neutrophils and generating pre-metastatic niche in lung

    by Abhishek Tyagi, Sambad Sharma, Kerui Wu, Shih-Ying Wu, Fei Xing, Yin Liu, Dan Zhao, Ravindra Pramod Deshpande, Ralph B. D’AGostino, Kounosuke Watabe


  • Open Access

    MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy

    by Ravindra Pramod Deshpande, Kerui Wu, Shih-Ying Wu, Abhishek Tyagi, Eleanor C Smith, Jee-Won Kim, Kounosuke Watabe

    We aimed to restore MHC-I expression on the surface of solid tumors including breast cancer and melanoma cells to regain sensitivity to immunotherapy and suppress metastatic progression. We screened a natural compound library and identified macbecin II as a reagent that upregulates MHC-I expression and induces antigen-dependent cell death in pre-invasive and invasive breast cancer models. Furthermore, we employed active immunotherapy using engineered small extracellular vesicles from dendritic cells (DCs) as a tumor vaccine (IL2-ep13nsEV) in combination with macbecin II for personalized breast cancer treatment. We found that macbecin II induced MHC-I-dependent antigen presentation and that IL2-ep13nsEV synergized with macbecin II inducing cell death, reducing metastasis, and boosting immune cell infiltration. In addition, macbecin II potentiated the effects of anti-PD-1 immunotherapy in suppressing tumor growth and metastasis. Mechanistically, macbecin II upregulated MHC-I expression post-translationally by rescuing it from lysosomal degradation. Our findings revealed a strong efficacy of macbecin II in regulating MHC-I expression and following antigen-dependent cell death. Therefore, combining active immunotherapies and macbecin II represents an effective strategy to prevent growth and progression of solid tumors including breast cancer and melanoma.


  • Retraction
    Open Access

    Retraction Note: Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasis

    by Abhishek Tyagi, Shih-Ying Wu, Sambad Sharma, Kerui Wu, Dan Zhao, Ravindra Deshpande, Ravi Singh, Wencheng Li, Umit Topaloglu, Jimmy Ruiz, et al.


  • Open Access

    Correction: Regucalcin promotes dormancy of prostate cancer

    by Sambad Sharma, Xinhong Pei, Fei Xing, Shih-Ying Wu, Kerui Wu, Abhishek Tyagi, Dan Zhao, Ravindra Deshpande, Marco Gabriel Ruiz, Ravi Singh, et al.

  • Functional evaluation of dendritic cells and extracellular vesicles as immunotherapy for breast cancer

    by Feng Lyu, Kerui Wu, Shih-Ying Wu, Ravindra Pramod Deshpande, Abhishek Tyagi, Isabella Ruiz, Sindhu Yalavarthi, Kounosuke Watabe

    Dendritic cells (DCs) play critical roles in recognizing and presenting antigens to T cells. They secrete dendritic cell-derived extracellular vesicles (DC-sEVs), which could mimic the function of DCs. Therefore, we explore the possibility of using DC-sEVs as a potential personalized vaccine in this study. We compared the efficacy of DCs and DC-sEVs on stimulating the immune system to target breast cancer cells and found that DC-sEVs had significantly more MHC molecules on the surface when compared to the parental DCs. In our in vivo and in vitro testing, Dc-sEVs showed significant advantages over DCs, regarding efficacy, safety, storage, and potential delivery advantages. DC-sEVs were able to suppress the growth of immune-cold breast tumors, while DCs failed to do so. These results indicate the strong potential utility of DC-sEVs as a personalized immunotherapy for breast cancer.


  • Open Access

    Editorial: Cellular and molecular characteristics of the pre-metastatic niche

    by Abhishek Tyagi

    Editorial: Cellular and molecular characteristics of the pre-metastatic niche


  • Open Access

    Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence

    by Kerui Wu, Feng Lyu, Shih-Ying Wu, Sambad Sharma, Ravindra Pramod Deshpande, Abhishek Tyagi, Dan Zhao, Fei Xing, Ravi Singh, Kounosuke Watabe

    Breast cancer has been shown to be resistant to immunotherapies. To overcome this challenge, we developed an active immunotherapy for personalized treatment based on a smart nanovesicle. This is achieved by anchoring membrane-bound bioactive interleukin 2 (IL2) and enriching T cell–promoting costimulatory factors on the surface of the dendritic cell–derived small extracellular vesicles. This nanovesicle also displays major histocompatibility complex–bound antigens inherited from tumor lysate–pulsed dendritic cell. When administrated, the surface-bound IL2 is able to guide the nanovesicle to lymphoid organs and activate the IL2 receptor on lymphocytes. Furthermore, it is able to perform antigen presentation in the replacement of professional antigen-presenting cells. This nanovesicle, named IL2-ep13nsEV, induced a strong immune reaction to rescue 50% of the mice in our humanized patient-derived xenografts, sensitized cancer cells to immune checkpoint inhibitor treatment, and prevented the recurrence of resected tumors. This paradigm presents a feasible strategy for the treatment and prevention of metastatic breast cancer.